News - Pricing


Current filters:


Popular Filters

590 to 614 of 675 results

Brain disorder bill hits 800 billion euros as Europe faces “ticking bomb,” warns EBC study


The annual cost of brain disorders in Europe has soared to 798 billion euros ($1,070 billion) in what…


AstraZeneca’s Brilique first to be assessed under Germany’s AMNOG, getting positive view


The German reimbursement body, the Federal Joint Committee (G-BA), has published the Institute for Quality…


Australian government U-turn on PBS listing of drugs


More than 160,000 Australians per year will benefit from the Australian Government’s decision to…

Asia-PacificBoehringer IngelheimPharmaceuticalPradaxaPricingRegulation

Portuguese hospitals block access to new medicines as retail drug sector expected to meet savings goal


Access to expensive medicines is becoming increasingly difficult in Portuguese public hospitals, while…

EuropeHealthcarePfizerPharmaceuticalPricingRare diseasesRegulationVyndaqel

Cost benefit analysis of cervical cancer vaccines sees Gardasil beat Cervarix


An analysis of cervical-cancer vaccine has shown that Merck & Co’s (NYSE: MRK) Gardasil (human papillomavirus…

CervarixEuropeGardasilGlaxoSmithKlineMerck & CoPharmaceuticalPricingVaccines

Canada’s national health spending crunch the result of public insurance programs, not drug costs


Claims that prescription drug costs are at the root of Canada’s health spending crisis are unfounded…

HealthcareNorth AmericaPharmaceuticalPricing

German pharma counts cost of drug pricing reforms


Recent government drug pricing reforms have cost the German pharmaceutical industry billions of euros,…


German drug pricing reforms lower health system’s costs, says AVR report


The multi-year uptrend in drug expenditure by Germany’s health insurers could be ending, according…


Use of generic Rx drugs saved US consumers and the health care system $931 billion over past 10 years, study finds


An independently conducted analysis showing that the use of generic prescription drugs in the USA has…

GenericsMarkets & MarketingNorth AmericaPricing

Experts stress the need to improve access to health care in India


Providing adequate access to medicines and health care is one of the most challenging issues being faced…


Impax confirms patent challenge to GlaxoSmithKline’s Jalyn; Albemarle hikes API prices


US generic drugmaker Impax Laboratories (Nasdaq: IPXL) confirms that it has initiated a challenge of…

AlbemarleAvodartGenericsGlaxoSmithKlineImpax LaboratoriesJalynLegalNorth AmericaPatentsPricing

SMC backs Celgene’s Vidaza for rare blood and bone marrow cancers in Scotland


The Scottish Medicines Consortium (SMC), the equivalent of the UK’s drug watchdog the National Institute…


Draft guidance from UK's NICE recommends clinical trial for COPD drug Daxas


New draft guidance from the UK's drug watchdog the National Institute for Health and Clinical Excellence…

DaxasEuropeMerck & CoNycomedPharmaceuticalPricingRegulationRespiratory and Pulmonary

Takeda’s Mepact backed by UK’s NICE for osteosarcoma, after previous negative opinion


In a U-turn by the UK drug watchdog, in its latest appraisal, the National Institute for Health and Clinical…

EuropeMepactOncologyPharmaceuticalPricingRegulationTakeda Pharmaceuticals

Erbitux and Gilenya added to Australia’s PBS listing


More than 400,000 Australians will benefit from new subsidized medicines, effective September 1, as Minister…

Asia-PacificErbituxGilenyaMerck KGaANeurologicalNovartisOncologyPharmaceuticalPricingRegulation

PCMA outlines $100 billion in Rx drug savings in USA


As the USA’s Joint Select Committee on Deficit Reduction examines options to reduce the deficit…

BiotechnologyGenericsHealthcareNorth AmericaPharmaceuticalPricingRegulation

Pfizer’s Pristiq sees private plan formulary access similar to Lilly’s Cymbalta


In the USA, similar percentages of private health plan lives have formulary access to Pfizer’s (NYSE:…

CymbaltaEli LillyHealthcareNeurologicalNorth AmericaPfizerPharmaceuticalPricingPristiq

Long-term outlook and predictability key to successful medicines policy for Australia, conference told


A predictable regulatory and reimbursement environment, and a long-term policy outlook are essential…


BASF hikes prices for pharmaceutical excipients and active ingredients


Effective September 1, 2011, Germany-based BASF (BAS: XE), the world’s largest chemical company,…


Diabetes treatments now 8.4% of UK annual NHS drugs bill, says report


Diabetes prescriptions now account for 8.4 per of the entire National Health Service net bill for primary…

DiabetesEuropeHealthcareMarkets & MarketingPharmaceuticalPricing

AstraZeneca breast cancer drug Faslodex not good use of NHS resources, says NICE draft guidance


An independent committee of experts that develops guidance on behalf of the UK drugs watchdog the National…


590 to 614 of 675 results

Back to top